Clinical trials: Urinary System Tumor
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Carcinoma, Renal Cell
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long…
- Trial name
- NCT03538717
- Where
- 40 sites in Spain
- Volunteers
- 157 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor…
- Trial name
- NCT01152801
- Testing
- Everolimus (RAD001)
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Trial name
- NCT01672775
- Testing
- AGS-16C3F
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Agensys, Inc.
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Malignancies, Metastatic Cancer
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT02923349
- Testing
- INCAGN01949
- Where
- 8 sites in United States, Spain and 2 more
- Volunteers
- 87 people
- Sponsor
- Incyte Biosciences International Sàrl
Kidney Cancer
A Prospective Post-Market Study to Evaluate the Clinical Utility of IRIS, a Three-dimensional (3-D) Anatomical Modeling Software for Pre-operative Surgical Planning and Intra-operative Navigation for Nephrectomy
This is a prospective, multi-center, post-market study to evaluate the clinical utility of IRIS, a 3D anatomical modeling software, with standard CT scans during pre-operative planning and intra-operative navigation for…
- Trial name
- NCT04329767
- Testing
- IRIS 1.0
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- Intuitive Surgical
Non Muscle Invasive Bladder Cancer
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
This is a prospective, single-arm study evaluating the safety and efficacy of NDV01 KIT, a fixed-dose combination of gemcitabine HCl and docetaxel, administered via intravesical instillation in patients with high-grade Non-Muscle…
- Trial name
- NMIBC (NCT06663137)
- Testing
- NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- Relmada Therapeutics, Inc.
Carcinoma, Renal Cell
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer.
- Trial name
- NCT00502307
- Testing
- Tivozanib (AV-951)
- Where
- 26 sites in India, Russia and 1 more
- Volunteers
- 272 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
The purpose of this study is to test the safety of an investigational vaccine called TroVax when given in conjunction with Interleukin-2 (IL-2) treatment.
- Trial name
- NCT00083941
- Testing
- TroVax, Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oxford BioMedica
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Renal Cell Carcinoma, Melanoma
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4…
- Conditions
- Renal Cell Carcinoma, Melanoma, Lung Cancer
- Trial name
- NCT02763761
- Testing
- Infliximab + Prednisone, Methylprednisolone + Prednisone
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Renal Cell
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
This is an open-label, international, multi-center study designed to provide access to pazopanib for subjects who have been enrolled in the Phase III renal cell carcinoma study (VEG105192) and have progressed on placebo.
- Trial name
- NCT00387764
- Testing
- pazopanib
- Where
- 58 sites in Argentina, Australia and 18 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell, Prostatic Neoplasms
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable…
- Trial name
- NCT00106301
- Testing
- FK228 (romidepsin)
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Celgene
Renal Cell Carcinoma
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa.
- Trial name
- INTORACT (NCT00631371)
- Testing
- Bevacizumab, Temsirolimus, Interferon-Alfa 9MU
- Where
- 172 sites in United States, Argentina and 28 more
- Volunteers
- 791 people
- Sponsor
- Pfizer
Renal Cancer, Tumors
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sorafenib will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of…
- Trial name
- NCT00398814
- Testing
- Perifosine, Sorafenib
- Volunteers
- 30 people
- Sponsor
- AEterna Zentaris
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Solid Tumor, Non Small Cell Lung Cancer
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT03343613
- Testing
- LY3381916, LY3300054
- Where
- 12 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.